Re-submission of the Audited Financial Results of the Company for quarter and year ended March 31, 2025 in Machine-Readable Format
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science has resubmitted its audited consolidated financial results for the quarter and year ended March 31, 2025 in machine-readable format, as directed by NSE on June 23, 2025. The underlying results show consolidated revenue from continuing operations of Rs. 4,565 crore for FY25, up about 17% from Rs. 3,890 crore in FY24 (restated). Profit after tax from continuing operations swung to Rs. 409 crore from a loss of Rs. 144 crore in the prior year. Total profit for the period was Rs. 3,598 crore, which includes a one-time gain of Rs. 3,188 crore from the demerger of the CDMO and Soft Gelatin businesses (approved by NCLT in November 2024 with a retrospective appointed date of April 1, 2024). The board had earlier, on May 22, 2025, approved a final dividend of Rs. 4 per share (40%). Auditor BSR & Co. LLP issued an unmodified opinion with an emphasis of matter on the restatement of FY24 figures.
This filing is procedural — the same audited results that were originally disclosed on May 22, 2025, so no fresh material information for shareholders. The underlying numbers indicate a strong turnaround in continuing operations, but investors should treat the Rs. 3,188 crore demerger gain as a one-time exceptional item, not recurring earnings. The 40% final dividend is a positive signal of cash returns.